These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
☐
|
Preliminary Proxy Statement
|
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
☒
|
Definitive Proxy Statement
|
|
|
☐
|
Definitive Additional Materials
|
|
|
☐
|
Soliciting Material Under Rule 14a-12
|
|
|
☒
|
No fee required.
|
|
|
|
☐
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
|
|
|
|
1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
4)
|
Proposed maximum aggregate value of transaction:
|
|
|
|
5)
|
Total fee paid:
|
|
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
|
|
☐
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:
|
|
|
|
1)
|
Amount previously paid:
|
|
|
|
2)
|
Form, Schedule or Registration Statement No:
|
|
|
|
3)
|
Filing Party:
|
|
|
|
4)
|
Date Filed:
|
|
|
1.
|
elect the three Class III directors listed in the proxy statement, whose terms expire in 2022;
|
|
2.
|
ratify the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for 2019;
|
|
3.
|
approve, in a non-binding, advisory vote, the compensation paid to our named executive officers; and
|
|
4.
|
transact any other business that may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
|
|
By order of the Board of Directors,
/s/ Isaac Angel
Isaac Angel
Chief Executive Officer
|
| 1. |
elect the three Class III directors listed in the accompanying proxy statement, whose terms expire in 2022;
|
| 2. |
ratify the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for 2019;
|
| 3. |
approve, in a non-binding, advisory vote, the compensation paid to our named executive officers; and
|
| 4. |
transact any other business that may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| · |
This Proxy Statement and 2018 Annual Report to Stockholders, which includes the Annual Report on Form 10-K for the year ended December 31, 2018 are available at
http://materials.proxyvote.com/686688
.
|
|
April 2, 2019
|
/s/Isaac Angel
Isaac Angel
Chief Executive Officer |
|
i
|
|
|
1
|
|
|
1
|
|
|
6
|
|
|
10
|
|
|
10
|
|
|
10
|
|
|
11
|
|
|
11
|
|
|
11
|
|
|
15
|
|
|
15
|
|
|
15
|
|
|
15
|
|
|
16
|
|
|
16
|
|
|
17
|
|
|
19
|
|
|
20
|
|
|
21
|
|
|
24
|
|
|
32
|
|
|
33
|
|
|
33
|
|
|
35
|
|
|
38
|
|
|
40
|
|
|
40
|
|
|
42
|
|
|
43
|
|
|
44
|
|
|
47
|
|
|
49
|
|
|
50
|
|
|
51
|
|
|
51
|
| (i) |
vote to elect the three Class III directors listed herein whose terms expire in 2022;
|
| (ii) |
vote to ratify the appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited (“PwC ISR”) as our independent registered public accounting firm for 2019;
|
| (iii) |
vote to approve, in a non-binding, advisory vote, the compensation of our named executive officers (“NEOs”); and
|
| (iv) |
transact any other business that may properly come before the Annual Meeting.
|
| · |
By Internet - You may submit your proxy by going to www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You will need the Notice or proxy card in order to vote by Internet.
|
| · |
By Telephone - You may submit your proxy by using a touch-tone telephone to call toll-free 1-800-776-9437 in the United States or 1-718-921-8500 from foreign countries and following the instructions. You will need the Notice or proxy card in order to vote by telephone.
|
| · |
By Mail - You may vote by mail by requesting a proxy card from us, indicating your vote by completing, signing and dating the card where indicated and by mailing or otherwise returning the card in the envelope that will be provided to you. You should sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity, indicate your name and title or capacity.
|
| · |
Proposal
1: elect the three Class III directors listed in this Proxy Statement (the “Nominee Proposal”);
|
| · |
Proposal
2: ratify the appointment of PwC ISR as our independent registered public accounting firm for 2019 (the “Ratification Proposal”); and
|
| · |
Proposal
3: approve the compensation of our NEOs on an advisory basis (the “Say-on-Pay Proposal”).
|
| ● |
by
signing
and delivering another proxy with a later date that is received no later than May 20, 2019;
|
| ● |
by voting again by Internet or telephone at a later time before the closing of those voting facilities at 11:59 p.m. (Eastern Daylight Time) on May 20, 2019;
|
| ● |
by sending a written statement to that effect to the Company’s Corporate Secretary, provided that such statement is received no later than May 20, 2019; or
|
| ● |
by voting in person at the Annual Meeting.
|
|
Proposal
|
Vote Required
|
Voting Options
|
Board
Recommendation (1) |
Broker
Discretionary Voting Allowed |
Impact of
Abstain Vote |
|
Proposal 1 –
Nominee Proposal |
Majority of votes cast – "FOR" must exceed "AGAINST" votes
|
"FOR"
"AGAINST" "ABSTAIN" |
"FOR"
|
No
|
None
|
|
Proposal 2 –
Ratification Proposal |
Majority of votes present in person or represented by proxy and entitled to vote on this item of business
|
"FOR"
"AGAINST" "ABSTAIN" |
"FOR"
|
Yes
|
"AGAINST"
|
|
Proposal 3 –
Say-on-Pay Proposal |
Majority of votes present in person or represented by proxy and entitled to vote on this item of business
|
"FOR"
"AGAINST" "ABSTAIN" |
"FOR"
|
No
|
"AGAINST"
|
|
(1)
|
If you are a registered holder and you sign and submit your proxy card without indicating your voting instructions, your shares will be voted in accordance with the Board’s recommendation.
|
|
|
Audit Committee
|
Compensation
Committee
|
Nominating and
Corporate Governance
Committee |
Investment
Committee |
|
Ravit Barniv*
|
X, Chair
|
X
|
X
|
|
|
Dan Falk*
|
X, Chair
|
X
|
X
|
|
|
Todd C. Freeland*
|
X
(1)
|
X, Chair
(1)
|
||
|
David Granot*
|
X
|
X
|
X
|
X, Chair
|
|
Stan H. Koyanagi*
|
||||
|
Yuichi Nishigori*
|
X
(2)
|
|||
|
Dafna Sharir*
|
||||
|
Stanley B. Stern*
|
X
|
|||
|
Byron G. Wong*
|
X
|
| (1) |
Appointed to serve on the Compensation Committee and Nominating and Corporate Governance Committee in accordance with the terms of the Governance Agreement.
|
| (2) |
Appointed to serve on the Investment Committee in accordance with the terms of the Governance Agreement.
|
| * |
Independent director
|
| · |
making recommendations to our Board as to changes in Ormat’s general compensation philosophy;
|
| · |
making
recommendations to our Board with respect to the adoption, amendment, termination or replacement of incentive compensation, equity-based plans or other compensation plans, policies and programs;
|
| · |
overseeing
the development and implementation of such incentive compensation, equity-based plans or other compensation plans, policies and programs;
|
| · |
establishing
performance goals and metrics under any such plan, policy or program and certifying attainment of any such performance goals and metrics, including for purposes of Section 162(m); and
|
| · |
monitoring
Ormat’s compliance with SEC rules and regulations regarding stockholder approval of certain executive compensation.
|
|
2018 ($)
|
2017 ($)
|
|
|
Audit Fees
(1)
|
5,739,773
|
2,460,240
|
|
Audit-Related Fees
(2)
|
85,000
|
546,585
|
|
Tax Fees
(3)
|
1,478,339
|
948,306
|
|
All Other Fees
(4)
|
3,870
|
43,870
|
|
Total
:
|
7,306,982
|
3,999,001
|
| (1) |
Audit
Fees
represent the aggregate fees billed for the audits of the annual financial statements and the Company’s internal control over financial reporting; for review of the financial statements included in the Company’s Form 10-Q filings; for the audits and reviews of certain of our subsidiaries; and for services that are normally provided by the independent registered public accounting firm in connection with statutory and regulatory filings.
Audit fees for the year ended 2018 increased compared to 2017 mainly due to fees associated with our identification of a material weakness related to taxes in the fourth quarter of 2017 and the additional work in connection with the identification of such material weakness as well as the restatement of second, third and fourth quarter financial statements and its full-year 2017 financial statements.
|
| (2) |
Audit-
Related
Fees represent the aggregate fees billed for services related to the performance of the audit or review of our financial statements and that are not reported under paragraph (1) above, due diligence related to mergers and acquisitions and consulting on financial accounting/reporting standards.
|
| (3) |
Tax
Fees
represent the aggregate fees billed for international tax compliance, tax advice, and tax planning services.
|
| (4) |
All
Other
Fees represent annual software license fees.
|
|
|
Dan Falk, Chair
David Granot
Stanley B. Stern
Byron G. Wong
|
|
Name
|
Age
|
Position
|
|
Isaac Angel
|
62
|
Chief Executive Officer
|
|
Doron Blachar
|
51
|
Chief Financial Officer
|
|
Zvi Krieger
|
63
|
Executive Vice President—Electricity Segment
|
|
Shlomi Argas
|
54
|
Executive Vice President—Operations and Products
|
|
Bob Sullivan
|
55
|
Executive Vice President—Business Development, Sales and Marketing
|
|
Hezi Kattan
|
44
|
General Counsel & Chief Compliance Officer
|
|
BENEFICIAL OWNERS OF MORE THAN 5%
|
AMOUNT AND NATURE OF BENEFICIAL OWNERSHIP
|
PERCENT OF COMMON STOCK OUTSTANDING
|
|
ORIX CORPORATION
|
10,988,577
(1)
|
22.1%
|
|
THE VANGUARD GROUP
|
3,826,799
(2)
|
7.55%
|
|
BLACKROCK, INC.
|
3,268,703
(3)
|
6.5%
|
|
CLAL INSURANCE ENTERPRISES HOLDINGS LTD.
|
3,206,744
(4)
|
6.33%
|
|
MIGDAL INSURANCE & FINANCIAL HOLDINGS LTD
|
3,071,265
(5)
|
6.06%
|
|
MENORA MIVTACHIM HOLDINGS LTD.
|
3,067,598
(6)
|
6.05%
|
|
DIRECTORS AND NAMED EXECUTIVE OFFICERS
|
||
|
RAVIT BARNIV
††
|
17,120
(7)
|
*
|
|
DAN FALK
††
|
17,120
(8)
|
*
|
|
STANLEY B. STERN
††
|
17,887
(9)
|
*
|
|
DAVID GRANOT
††
|
16,361
(10)
|
*
|
|
TODD C. FREELAND
††
|
8,944
(11)
|
*
|
|
STAN H. KOYANAGI
††
|
7,500
(12)
|
*
|
|
YUICHI NISHIGORI
††
|
7,500
(13)
|
*
|
|
BYRON G. WONG
††
|
7,500
(14)
|
*
|
|
DAFNA SHARIR
††
|
1,207
(15)
|
*
|
|
ISAAC ANGEL
†
|
173,592
(16)
|
*
|
|
DORON BLACHAR
†
|
61,981
(17)
|
*
|
|
ZVI KRIEGER
†
|
23,943
(18)
|
*
|
|
BOB SULLLIVAN
††
|
28,875
(19)
|
*
|
|
SHLOMI ARGAS
†
|
23,943
(20)
|
*
|
|
DIRECTORS AND EXECUTIVE OFFICERS AS A GROUP (15 PERSONS)
|
413,473
(21)
|
*
|
| (1) |
Based
on Schedule 13D filed with the SEC on August 3, 2017 by ORIX. ORIX’s address is Hamamatsucho Building, 1-1-1 Shibaura, Minato-ku, Tokyo 105-0023, Japan.
|
| (2) |
Based
on
Schedule 13G/A (Amendment No. 3) filed with the SEC on February 11, 2019 by The Vanguard Group (“Vanguard”). Includes, as of December 31, 2018, 3,826,799 shares beneficially owned, consisting of 40,851 shares as to which Vanguard has sole voting power, 10,634 as to which Vanguard has shared voting power, 3,778,650 shares as to which Vanguard has sole dispositive power and 48,149 shares as to which Vanguard has shared dispositive power. Vanguard’s address is 100 Vanguard Blvd., Malvern, PA 19355.
|
| (3) |
Based
on
Schedule 13G filed with the SEC on February 8, 2019 by BlackRock Inc. Includes, as of December 31, 2018, 3,268,703 shares beneficially owned, consisting of 3,173,298 shares as to which BlackRock has sole power to vote or to direct the vote. BlackRock’s address is 55 East 52nd Street, New York, NY 10055.
|
| (4) |
Based
on
Schedule 13G/A filed with the SEC on February 14, 2019 by Clal Insurance Enterprises Holdings Ltd. (“Clal”) and IDB Development Corporation Ltd. Includes, as of December 31, 2018, (i) 3,086,150 shares held for members of the public through, among others, provident funds and/or pension funds and/or insurance policies, which are managed by subsidiaries of Clal, which subsidiaries operate under independent management and make independent voting and investment decisions and (ii) 120,594 shares beneficially held for Clal’s account. Clal’s address is 36 Raul Walenberg St., Tel Aviv 66180, Israel.
|
| (5) |
Based
on
Schedule 13G filed with the SEC on February 14, 2019 by
Migdal Insurance & Financial Holdings Ltd
(“Migdal”). Includes, as of December 31, 2018,
(i) 3,006,437 Ordinary Shares held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, and (ii) 164,689 Ordinary Shares held by companies for the management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent voting and investment decisions, and (iii) 64,828 beneficially held for their own account (Nostro account). Migdal’s address is
4 Efal Street; P.O. Box 3063; Petach Tikva 49512, Israel
.
|
| (6) |
Based
on Schedule 13G/A filed with the SEC on February 11, 2019 by Menora Mivtachim Holdings Ltd. (“Menora”)
and by entities that are direct or indirect, wholly-owned or majority-owned, subsidiaries of Menora Holdings (the “Subsidiaries”), such as Menora Mivtachim Insurance Ltd., Shomera Insurance Company Ltd., Menora Mivtachim Pensions and Gemel Ltd., and Menora Mivtachim Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd.
, Includes, as of December 31, 2018, (i)
2,448,352 shares beneficially owned by Menora Mivtachim Pensions and Gemel Ltd.; (ii) 563,250 shares beneficially owned by Menora Mivtachim Insurance Ltd.; (iii) 48,590 shares beneficially owned by Menora Mivtachim
Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd.
; and (iv) 7,407 shares beneficially owned by Shomera Insurance Company Ltd. Menora’s address
is Menora House, 23 Jabotinsky St., Ramat Gan 5251102, Israel.
|
| (7) |
Includes
15,000 shares of Common Stock underlying options and 1,361 shares of Common Stock underlying Stock Appreciation Rights (“SARs”).
|
| (8) |
Includes
15,000 shares of Common Stock underlying options and 1,361 shares of Common Stock underlying SARs.
|
| (9) |
Includes
15,000 shares of Common Stock underlying options and 1,361 shares of Common Stock underlying SARs.
|
| (10) |
Includes
15,000 shares of Common Stock underlying options and 1,361 shares of Common Stock underlying SARs.
|
| (11) |
Includes
7,500 shares of Common Stock underlying options and 681 shares of Common Stock underlying SARs.
|
| (12) |
Includes
7,500 shares of Common Stock underlying options.
|
| (13) |
Includes
7,500 shares of Common Stock underlying options.
|
| (14) |
Includes
7,500 shares of Common Stock underlying options.
|
| (15) |
Includes
772 shares of Common Stock underlying SARs.
|
| (16) |
Includes
164,877 shares of Common Stock underlying SARs.
|
| (17) |
Includes
59,563 shares of Common Stock underlying SARs.
|
| (18) |
Includes
23,609 shares of Common Stock underlying SARs.
|
| (19) |
Includes
23,609 shares of Common Stock underlying SARs.
|
| (20) |
Includes
23,609 shares of Common Stock underlying SARs.
|
| (21) |
Includes
90,000 shares of Common Stock underlying options and 315,843 shares of Common Stock underlying SARs and 21,309 shares of Common Stock underlying RSUs.
|
| · |
the
information
set forth in the “Compensation Discussion and Analysis” section of this Proxy Statement, which describes our compensation objectives and the various elements of our compensation program and policies applicable to our named executive officers; and
|
| · |
the
tables
, narrative disclosures and other information set forth in the “Executive Compensation” section of this Proxy Statement, which describes how we have compensated our named executive officers.
|
| 1. |
Annual salary, our short-term element of compensation which is paid monthly, is intended to provide a predictable annual income at a level consistent with the individual contributions of our executive officers.
|
| 2. |
Annual bonuses, our medium-term element of compensation which are paid annually to our executive officers, are intended to link our executive officers’ compensation to the Company’s overall performance, as well as, in most cases, their individual achievements.
|
| 3. |
Equity awards, our long-term element of compensation, are designed to promote long-term leadership and align the interests of our executive officers with those of our stockholders, while their vesting schedule assists us in retaining our executive officers. Equity awards for our NEOs typically vest 50% on the two year anniversary and 25% on each of the three and four year anniversaries of the date of grant. All employees and consultants of the Company are eligible to receive equity awards pursuant to our Amended and Restated 2018 Incentive Compensation Plan (the “2018 ICP”). The term of our equity awards typically ranges from six to ten years from the date of grant with respect to grants to our current executive officers.
|
|
NEO
|
Revenue
|
Adjusted EBITDA
|
Individual Performance Criteria
|
CEO Goals
|
|
Doron Blachar, Chief Financial Officer
|
20%
|
20%
|
35%
|
25%
|
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
10%
|
10%
|
60%
|
20%
|
|
Shlomi Argas, Executive Vice President, Product Segment and Operations
|
17.5%
|
17.5%
|
40%
|
25%
|
|
Bob Sullivan, Executive Vice President, Business Development Sales and Marketing
|
20%
|
20%
|
30%
|
30%
|
|
Company Performance Metric
|
Target
|
Actual
|
|
Revenue
|
$689
|
$680
|
|
Adjusted EBITDA
|
$339
|
$346
|
|
NEO
|
Revenue
|
Adjusted EBITDA
|
Individual Performance Criteria
|
CEO Goals
|
|
Doron Blachar, Chief Financial Officer
|
8.6%
|
14.8%
|
5.5%
|
8.3%
|
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
4.3%
|
7.4%
|
16.3%
|
20%
|
|
Shlomi Argas, Executive Vice President, Product Segment and Operations
|
7.5%
|
13.0%
|
29.3%
|
25%
|
|
Bob Sullivan, Executive Vice President, Business Development Sales and Marketing
|
8.6%
|
14.8%
|
15.9%
|
20%
|
|
NEO
|
% of Award Earned Paid Out
|
|
Doron Blachar, Chief Financial Officer
|
37%
|
|
Zvi Krieger, Executive Vice President, Electricity Segment
|
48%
|
|
Shlomi Argas, Executive Vice President, Product Segment and Operations
|
75%
|
|
Bob Sullivan, Executive Vice President, Business Development Sales and Marketing
|
59%
|
|
Name
|
SARs (#)
|
RSUs (#)
|
|
Isaac Angel
|
249,899
|
39,615
|
|
Zvi Krieger
|
30,833
|
4,320
|
|
Shlomi Argas
|
30,833
|
4,320
|
|
Bob Sullivan
|
26,667
|
3,736
|
|
|
Ravit Barniv, Chair
Dan Falk Todd C. Freeland David Granot |
|
Name and Principal Position
|
Year
|
Salary ($)
|
Bonus ($)
|
Stock
Awards ($)
(1)
|
Option
Awards ($)
(2)
|
Non-Equity Incentive Plan Compensation
($)
(3)
|
All Other
Compensation ($)
|
Total ($)
|
|
Isaac Angel, Chief Executive Officer
|
2018
|
594,206
|
-
|
2,148,379
|
4,298,022
|
800,000
|
143,944
(4)
|
7,984,551
|
|
2017
|
469,030
|
–
|
–
|
–
|
762,500
|
124,905
|
1,356,435
|
|
|
2016
|
426,294
|
–
|
–
|
1,198,000
|
750,000
|
111,788
|
2,486,082
|
|
|
Doron Blachar, Chief Financial Officer
|
2018
|
373,424
|
-
|
--
|
--
|
100,000
|
100,348
(5)
|
573,772
|
|
2017
|
361,907
|
–
|
606,372
|
1,173,934
|
215,000
|
99,984
|
2,457,197
|
|
|
2016
|
336,391
|
–
|
–
|
509,150
|
215,345
|
90,261
|
1,151,147
|
|
|
Zvi Krieger,
Executive Vice President, Electricity Segment
|
2018
|
286,923
|
-
|
225,017
|
451,311
|
101,000
|
84,365
(6)
|
1,148,616
|
|
2017
|
265,633
|
–
|
83,830
|
162,334
|
210,000
|
86,219
|
808,016
|
|
|
2016
|
228,731
|
–
|
–
|
509,150
|
142,783
|
74,245
|
954,909
|
|
|
Shlomi Argas, Executive Vice President, Product Segment and Operations
|
2018
|
283,064
|
-
|
225,017
|
451,311
|
154,000
|
92,764
(7)
|
1,206,156
|
|
2017
|
227,346
|
–
|
83,830
|
162,334
|
154,000
|
79,877
|
707,387
|
|
|
Bob Sullivan, Executive Vice President, Business Development, Sales and Marketing
|
2018
|
225,000
|
-
|
194,598
|
390,318
|
100,000
|
66,767
(8)
|
976,683
|
|
2017
|
225,000
|
–
|
83,830
|
162,334
|
75,000
|
64,839
|
611,003
|
|
|
2016
|
225,172
|
–
|
–
|
509,150
|
121,196
|
55,754
|
911,272
|
| (1) |
Represents the grant date fair value of all RSU awards, which are calculated in accordance with the accounting standards for share-based compensation using
Ormat’s
closing stock price on the next day of business following the date of grant. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
| (2) |
Represents the grant date fair value of SARs awards. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised. The fair value of each grant of stock-based awards on the date of grant is estimated using the Exercise Multiple-Based Lattice SAR-Pricing Model and the assumptions noted in the following table.
|
|
Year Ended December 31,
|
||||||||||||
|
2018
|
2017
|
2016
|
||||||||||
|
Risk-free interest rates
|
2.8
|
%
|
1.9
|
%
|
1.3
|
%
|
||||||
|
Expected lives (in years)
|
3.5
|
3.1
|
4.5
|
|||||||||
|
Dividend yield
|
0.90
|
%
|
0.62
|
%
|
1.1
|
%
|
||||||
|
Expected volatility
|
25.5
|
%
|
25.1
|
%
|
30.7
|
%
|
||||||
|
Forfeiture rate
|
3.1
|
%
|
0.0
|
%
|
8.4
|
%
|
||||||
| (3) |
This column reflects cash awards for the CEO pursuant to his employment agreement and the amount of any cash awards granted under the Management Plan to
other
NEOs. These amounts reflect cash awards earned under the Management Plan for 2018 which are paid in 2019.
|
| (4) |
Includes
payments
of car-related expenses in the amount of $26,075; Israel National Insurance in the amount of $10,030; U.S. Social Security in the amount of $9,181; health insurance in the amount of $246; convalescence pay in the amount of $1,719; Education Fund in the amount of $3,924
and perquisites amounting to $4,653.
|
| (5) |
Includes payments of car-related expenses in the amount of $22,512; Israel National Insurance in the amount of $10,030; health insurance in the amount of $67; convalescence pay in the amount of $1,719; Education Fund in the amount of $3,924; and perquisites amounting to $3,357.
|
| (6) |
Includes payments of car-related expenses in the amount of $13,887; Israel National Insurance in the amount of $10,030; health insurance in the amount of $67; convalescence pay in the amount of $1,719; Education Fund in the amount of $3,924; vacation redemption in the amount of $6,321and perquisites amounting to $4,727.
|
| (7) |
Includes payments of car-related expenses in the amount of $13,121; Israel National Insurance in the amount of $10,030 health insurance in the amount of $67; convalescence pay in the amount of $1,719; Education Fund in the amount of $3,924; and perquisites amounting to $4,939.
|
| (8) |
Includes payments of social security in the amount of $31,753; health insurance in the amount of $23,014
and 401(k) plan contributions amounting to $12,000.
|
|
Name
|
Type of Award
|
Grant Date
|
Estimated Future Payouts
Under Non-Equity Incentive Plan Compensation (4) |
All Other Stock Awards: Number of Shares of Stock or Units (#)
(2)
|
All Other Option Awards: Number of Securities Underlying
Options(#)
(3)
|
Exercise or Base Price of Option Awards ($/Sh)
|
Grant Date Fair Value of Stock and Option
Awards ($)
(1)
|
||
|
Threshold
($)
|
Target
($)
|
Maximum
($)
|
|||||||
|
Isaac
Angel
|
Annual
Cash
Incentive
|
150,000
|
N/A
|
900,000
|
|||||
|
RSU
|
5/8/2018
|
39,615
|
—
|
2,148,379
|
|||||
|
SAR
|
5/8/2018
|
249,899
|
55.16
|
4,298,022
|
|||||
|
Doron
Blachar
|
Annual Cash
Incentive
|
30,514
|
163,757
|
297,000
|
|||||
|
Zvi
Krieger
|
Annual Cash
Incentive
|
23,479
|
117,395
|
211,311
|
|||||
|
RSU
|
6/25/2018
|
4,320
|
-
|
225,017
|
|||||
|
SAR
|
6/25/2018
|
30,833
|
53.44
|
451,311
|
|||||
|
Shlomi
Argas
|
Annual Cash
Incentive
|
22,679
|
113,395
|
204,111
|
|||||
|
RSU
|
6/25/2018
|
4,320
|
-
|
225,017
|
|||||
|
SAR
|
6/25/2018
|
30,833
|
53.44
|
451,311
|
|||||
|
Bob
Sullivan
|
Annual Cash
Incentive
|
18,750
|
93,750
|
168,750
|
|||||
|
RSU
|
6/25/2018
|
3,736
|
-
|
194,598
|
|||||
|
SAR
|
6/25/2018
|
26,666
|
53.44
|
390,318
|
|||||
| (1) |
These amounts are the grant date fair value of (i) each SAR award, computed in accordance with accounting guidance for stock compensation using the binomial valuation model and (ii) each RSU awards, calculated in accordance with the accounting standards for share-based compensation using Ormat’s closing stock price on the next day of business following the date of grant.
|
| (2) |
Represents RSUs granted to our NEOs. The awards are discussed under the heading “Compensation Discussion and Analysis-Determination of Amounts and Formulas for Compensation-Equity Awards”.
|
| (3) |
Represents SARs granted to our NEOs. The awards are discussed under the heading “Compensation Discussion and Analysis-Determination of Amounts and Formulas for Compensation-Equity Awards”.
|
| (4) |
Represents the Threshold, Target and Maximum cash payout opportunities for fiscal 2018 under the annual incentive plan. For a further discussion of the payout opportunities, see “Compensation Discussion and Analysis—Determination of Amounts and Formulas for Compensation-Annual Bonus
|
| · |
Salary
: Annual gross salary of
NIS2,141,000
(equal to
approximately $571,249 based on the representative exchange rate set by the Bank of Israel on December 31, 2018), which is linked to the Israeli consumer price index.
|
| · |
Annual Performance Bonus
: If the Company’s annual consolidated net income is above $20 million, an annual bonus calculated as follows: 75% of the annual bonus will be based on achievement of specific performance metrics that measure the financial performance of the Company (the “Financial Performance Bonus”) and 25% of the annual bonus will be determined at the discretion of the Compensation Committee based on the achievement of other goals, such as diversity, social and environmental responsibility and merger and acquisition activities (the “KPI Bonus”). The Financial Performance Bonus is equal to (a) 0.75% of the Company's annual consolidated net income up to $50 million (inclusive) and (b) 1.00% of the portion of Company's annual consolidated net income that is above $50 million, if any; provided that the Financial Performance Bonus shall not exceed $675,000. The Annual KPI Bonus shall not exceed $225,000.
|
| · |
Equity grants:
|
| o |
Initial Grant
: Stock options granted on April 1, 2014 to purchase 100,000 shares of Common Stock at an exercise price of $29.52 per share, the closing price of our Common Stock on the date of grant, under the 2012 ICP. The stock options vest in one installment on the seven year anniversary of the date of grant and expire seven and a half years following the date of grant.
|
| o |
Second Grant
: Stock options granted on April 1, 2014
to purchase 300,000 shares of Common Stock at an exercise price equal to $29.52 per share, the closing price of our Common Stock on the date of grant, under the 2012 ICP. The stock options vest 25% on each of the two, three, four and five year anniversaries of the date of grant and expire six years following the date of grant.
|
| o |
Third Grant
: 100,000 SARs granted on June 14, 2016
with an exercise price equal to $42.87 per share of Common Stock underlying the SARs, the closing price of our Common Stock on the date of grant, under the 2012 ICP. The SARs vest in three equal installments on the two, three and four year anniversaries of the date of grant and expire seven years following the date of grant. The vesting period for these SARs was accelerated in connection with the ORIX Transaction. Please see Note (1) to the “Outstanding Equity Awards at Fiscal Year-End” table below.
|
| o |
Fourth Grant
: 294,889 SARs granted on May 8, 2018 with an exercise price equal to $55.16 per share of Common Stock underlying the SARs, the closing price of our Common Stock on the date of grant, and 36,915 RSUs, under the 2018 ICP. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs and SARs will vest 22%, 22%, 28% and 28%, respectively, on the one, two, three and four year anniversaries of the date of grant
.
|
| · |
Termination
: Each of the Company and Mr. Angel may terminate the employment agreement, for any reason, by providing six months’ prior notice of such termination (the “Notice Period”). Other than in the case of termination of employment by the Company for “Cause” (as defined in the employment agreement), Mr. Angel will be entitled to continue to receive his compensation during the Notice Period.
|
| · |
Termination in connection with a Change of Control
: In the event that Mr. Angel’s employment is terminated by the Company without “Cause”, or he resigns for a “Good Reason” (as defined in the employment agreement) within two (2) months before, or twelve months following, the consummation of a “Change of Control” (as defined in the Employment Agreement), Mr. Angel is entitled to the following: (i) the Notice Period (and consequently, the period during which compensation is payable to Mr. Angel) will be extended from six months to twelve months; and (ii) all the stock options and SARs described above will be accelerated and will become fully vested and exercisable.
|
|
Option Awards
|
Stock Awards
|
|||||
|
Name
|
Number of Securities
Underlying Unexercised Options (#) Exercisable
|
Number of Securities
Underlying Unexercised Options (#) Unexercisable
|
Option
Exercise Price ($)
|
Option Expiration Date
|
Number of
Shares or Units of Stock That Have NotVested (#) |
Market Value of
Shares or Units of StockThat Have Not Vested ($) (12) |
|
Isaac Angel
|
100,000
(1)
|
42.87
|
June 14, 2022
|
|||
|
-
|
-
|
30,900
(2)
|
1,616,070
|
|||
|
64,877
|
230,022
(3)
|
55.16
|
November 7, 2023
|
|||
|
Doron Blachar
|
42,500
(4)
|
42.87
|
June 14, 2021
|
|||
|
17,063
|
51,189
(5)
|
63.35
|
November 7, 2023
|
|||
|
—
|
—
|
7,253
(6)
|
379,332
|
|||
|
Zvi Krieger
|
21,250
|
21,250
(7)
|
42.87
|
June 14, 2021
|
||
|
2,359
|
7,079
(8)
|
63.35
|
November 7, 2023
|
|||
|
—
|
—
|
1,003
(9)
|
52,456
|
|||
|
-
|
4,320
(10)
|
225,936
|
||||
|
30,833
(11)
|
53.44
|
June 25, 2024
|
||||
|
Shlomi Argas
|
21,250
|
21,250
(7)
|
42.87
|
June 14, 2021
|
||
|
2,359
|
7,079
(8)
|
63.35
|
November 7, 2023
|
|||
|
—
|
—
|
1,003
(9)
|
52,456
|
|||
|
4,320
(10)
|
225,936
|
|||||
|
30,833
(11)
|
53.44
|
June 25, 2024
|
||||
|
Bob Sullivan
|
21,250
|
21,250
(7)
|
42.87
|
June 14, 2021
|
||
|
2,359
(5)
|
7,079
(8)
|
63.35
|
November 7, 2023
|
|||
|
1,003
(6)
|
52,456
|
|||||
|
--
|
3,736
(10)
|
195,391
|
||||
|
26,666
(11)
|
53.44
|
June 25, 2024
|
||||
|
|
(1)
|
The
vesting
period for these SARs was accelerated in connection with the ORIX Transaction and were subject to a lockup agreement entered into between Mr. Angel and the Company on May 4, 2017. As of November 2018, all 100,000 SARs were vested and are exercisable and the Common Stock acquired through the exercise may be sold, transferred or otherwise disposed.
|
| (2) |
Represents RSUs which will vest 22% on each of the first and second-year anniversaries of the vesting
commencement
date (November 7, 2017) and 28% on each of the third and the four-year anniversaries of the November 7, 2017 vesting commencement date. Each RSU represents the right to receive one share of Common Stock upon vesting
|
| (3) |
Represents SARs which will vest 22% on each of the first and the second year anniversaries of the
vesting
commencement date (November 7, 2017) and 28% on each of the third and four year anniversaries of the November 7, 2017. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
| (4) |
Represents SARs that were subject to an undertaking entered into between Mr. Blachar and the Company on May 4, 2017.
Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised. As of June 30, 2018, all shares of Common Stock acquired through the exercise of these SAR granted to Mr. Blachar on June 14, 2016 may be sold, transferred or otherwise disposed.
|
| (5) |
Represents
SARs which vest 25% on each of the one, two, three and four year anniversaries of the November 7, 2017 grant date. The SARs will become fully exercisable in November 2021. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
| (6) |
Represents
RSUs which vest 25% on each of the one, two, three- and four-year anniversaries of the November 7, 2017 grant date. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
| (7) |
Represents SARs which begin to vest two years after the June 14, 2016 grant date, with 50% of the SARs vesting on the second anniversary of the grant date and 25% of the SARs vesting on each of the third and
fourth
anniversaries of the grant date. The SARs will become fully exercisable in June 2020. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
| (8) |
Represents SARs which vest 25% on each of the one, two, three- and four-year anniversaries of the
November
7, 2017 grant date. The SARs will become fully exercisable in November 2021. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
| (9) |
Represents
RSUs which vest 25% on each of the one, two, three- and four-year anniversaries of the November 7, 2017 grant date. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
| (10) |
Represents
RSUs which will vest 50% on the second anniversary of the grant date, June 25, 2018, and 25% on each three and four year anniversaries of the grant date. The RSUs will become fully exercisable in June 2022. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
| (11) |
Represents
SARs which will vest 50% on the second anniversary of the grant date, June 25, 2018, and 25% on each three- and four-year anniversaries of the June 25 2018 grant date. The SARs will become fully exercisable in June 2022. Each SAR represents the right to receive shares of Common Stock with a value equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant
price
set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
| (12) |
The market value is based on the closing price of our Common Stock on December 31, 2018 of $52.30, multiplied by the number of units.
|
|
Options Awards
|
Stock Awards
|
|||
|
Name
|
Number of Shares Acquired on Exercise (#)
|
Value Realized on Exercise ($)
(1)
|
Number of Shares Acquired on Vesting (#)
|
Value Realized on Vesting ($)
(2)
|
|
Isaac Angel
|
-
|
-
|
8,715
|
463,289
|
|
Doron Blachar
|
-
|
-
|
2,418
|
128,541
|
|
Zvi Krieger
|
-
|
-
|
334
|
17,755
|
|
Shlomi Argas
|
-
|
-
|
334
|
17,755
|
|
Bob Sullivan
|
23,638(3)
|
1,327,420
|
334
|
17,755
|
|
(1)
|
Value realized on exercise is based on the difference between the aggregate exercise price and the fair market value of the shares acquired at the time of exercise.
|
|
(2)
|
Value realized on vesting is based on the fair market value of the shares at the time of vesting and includes the value of payments in lieu of fractional shares.
|
|
(3)
|
Represents amount of shares received upon exercise of 40,000 SARs.
|
|
Name
|
Termination without Cause ($)
|
Change in Control ($)
|
|
Isaac Angel
|
551,136
|
1,102,272
|
|
Doron Blachar
|
313,712
|
313,712
|
|
Zvi Krieger
|
510,045
|
510,045
|
|
Shlomi Argas
|
651,616
|
651,616
|
|
Bob Sullivan
|
–
|
–
|
| · |
Base annual retainer of $60,000 as fees related to their service on our Board.
|
| · |
Board and committee meeting fees are subject to an aggregate $35,000 cap, regardless of the number of meetings such director attends. The fees include:
|
| - |
$2,500 per day for each in-person Board meeting attended; $500 per day for each telephonic Board meeting attended; and $1,000 per day for telephonic participation in an in-person Board meeting.
|
| - |
$1,500 per day for each in-person committee meeting attended and $500 per day for each telephonic committee meeting attended.
|
| · |
The Chairs of the Audit Committee, Nominating and Corporate Governance Committee, Compensation Committee and Investment Committee receive supplemental annual cash retainers of $15,000, $10,000, $10,000 and $10,000, respectively, none of which are subject to the $35,000 cap.
|
| · |
The non-employee Chairman of the Board receives a supplemental annual retainer with an aggregate value of $100,000, consisting of a $40,000 cash retainer and equity compensation with a value of $60,000, as further described below.
|
| · |
We promptly reimburse all directors for transportation and lodging expenses actually incurred to attend meetings of our Board or committees.
|
|
Name
|
Fee Earned or Paid in Cash ($)
|
Stock Awards($) (1) |
Options Awards ($)
(2)
|
Total ($)
|
|
Ravit Barniv
|
105,000
|
24,000
|
96,000
|
225,000
|
|
Robert Clarke
|
36,500
(3)
|
-
|
-
|
36,500
|
|
Dan Falk
|
110,000
|
96,000
|
24,000
|
230,000
|
|
Todd C. Freeland
|
144,000
|
144,000
|
36,000
|
324,000
|
|
David Granot
|
104,350
|
96,000
|
24,000
|
224,350
|
|
Stan H. Koyanagi
|
-
(4)
|
-
(4)
|
24,000
|
24,000
|
|
Yuichi Nishigori
|
-
(5)
|
-
(5)
|
24,000
|
24,000
|
|
Dafna Sharir
|
53,000
|
144,000
|
36,004
|
233,004
|
|
Stanley B. Stern
|
87,500
|
96,000
|
24,000
|
207,500
|
|
Byron Wong
|
92,500
|
96,000
|
24,000
|
212,500
|
| (1) |
Represents the grant date fair value of RSU awards based on Ormat’s closing stock price on the next day of
business
following the date of grant. Each RSU represents the right to receive one share of Common Stock upon vesting.
|
| (2) |
Represents
the grant date fair value of SARs awards. For a discussion of the assumptions used in reaching this valuation, see footnote 3 to the Summary Compensation Table above.
|
| (3) |
Mr.
Clarke
has served as Director of the Company until May 7, 2018.
|
| (4) |
Mr.
Koyanagi
has elected to forego the cash retainer and the RSU awards to which members of our Board are entitled for 2018.
|
| (5) |
Mr.
Nishigori
has elected to forego the cash retainer and the RSU awards to which members of our Board are entitled for 2018.
|
|
Name
|
Unexercised Options Outstanding
|
Unexercised SARs Outstanding
|
Unvested RSUs Outstanding
|
|
Ravit Barniv
|
15,000
|
2,982
|
1825
|
|
Dan Falk
|
15,000
|
3,112
|
1,825
|
|
Todd C. Freeland
|
7,500
|
2,982
|
2,738
|
|
David Granot
|
15,000
|
1,621
|
1,825
|
|
Stan H. Koyanagi
|
7,500
|
1,621
|
-
|
|
Yuichi Nishigori
|
7,500
|
2,393
|
-
|
|
Dafna Sharir
|
-
|
2,982
|
1,825
|
|
Stanley B. Stern
|
15,000
|
1,621
|
1,825
|
|
Byron Wong
|
7,500
|
2,982
|
1,825
|
| · |
beneficially owning, individually or as part of a group, any class or series of voting securities of the Company in excess of 30% of the aggregate amount of the then-outstanding voting securities of such class or series;
|
| · |
engaging in any “solicitation” of “proxies” (as those terms are defined under Regulation 14A under the Exchange Act) relating to the election of directors with respect to the Company, becoming a “participant” (as such term is defined under Regulation 14A under the Exchange Act) in any solicitation seeking to elect directors not nominated by our Board or otherwise seeking to influence any person or group with respect to the voting of any voting securities of the Company other than with respect to ORIX’s director nominees;
|
| · |
voting in favor of or otherwise supporting any transaction that would result in a Change of Control (as defined in the Governance Agreement) of the Company, if the transaction is opposed by our Board;
|
| · |
making any public request or proposal seeking to have the Company waive or make amendments to our organizational documents in a manner that would either impede or facilitate a Change of Control of the Company; and
|
| · |
making any public request or proposal that the Company effect any material change to its dividend policy.
|
| · |
at the time ORIX and its affiliates collectively hold less than 5% of the voting power of all the outstanding voting securities of the Company;
|
| · |
upon the mutual written agreement of the Company and ORIX;
|
| · |
by ORIX, upon a material breach by the Company of the Governance Agreement that has not been cured within ten business days after written notice thereof has been received by the Company; or
|
| · |
by the Company, upon a material breach by ORIX of the Governance Agreement that has not been cured within ten business days after written notice thereof has been received by ORIX.
|
|
Number of
Securities to be Issued Upon
Exercise of Outstanding
Options, Warrants and Rights |
Weighted Average
Exercise Price of Outstanding Options, Warrants and Rights |
Number of Securities
Remaining Available for Future Issuance Under Equity Compensation Plans |
|
|
Equity Compensation plans approved
by security holders |
5,000,000*
|
$46.77
|
3,605,740†
|
|
Equity Compensation plans not approved by security holders
|
—
|
—
|
|
|
Total
|
5,000,000*
|
$46.77
|
3,605,740†
|
| * |
Stock options, SARs and RSUs were issued pursuant to the 2012 Incentive Compensation Plan (the “2012 ICP”) and the 2018 Incentive Compensation Plan that was approved at the 2018 Annual Stockholders Meeting (The “2018 ICP”) . Shares of our Common Stock to be issued upon exercise of these equity awards are registered on our Registration Statement on Form S-8 covering
4,000,000 shares filed with the SEC on May 18, 2012
and our Registration Statement filed with the SEC on May 8, 2018 covering 5,000,000 shares.
|
| † |
Following the approval at the 2018 Annual Meeting of Stockholders of our 2018 ICP n
o further awards will be granted under the 2012 ICP, though there are still unexercised options outstanding under the 2012 ICP.
|
|
PROXY VOTING INSTRUCTIONS
|
|
INTERNET
-
Access “
www.voteproxy.com
” and follow the on-screen instructions or scan the QR code with your smartphone. Have your proxy card available when you access the web page.
Vote online/phone until 11:59 PM EST the day before the meeting.
MAIL
-
Sign, date and mail your proxy card in the envelope provided as soon as possible.
IN PERSON
-
You may vote your shares in person by attending the Annual Meeting.
GO GREEN
-
e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible documents online, while reducing costs, clutter and paper waste. Enroll today via
www.astfinancial.com
to enjoy online access.
|
|
||
| COMPANY NUMBER | |||
| ACCOUNT NUMBER | |||
|
NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL
: The Notice of Meeting, proxy statement and proxy card are available at - http://materials.proxyvote.com/686688
|
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF DIRECTORS AND "FOR" PROPOSAL 2 AND 3.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENVELOPE PROVIDED. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE ☒
|
|||||||
|
|
|
|
1. |
Election of Directors.
|
|
|
|
|
|
|
|
FOR
|
AGAINST
|
ABSTAIN
|
||
|
|
|
|
(A) Dan Falk
|
☐
|
☐
|
☐
|
|
|
|
|
|
(B) Todd C. Freeland
|
☐
|
☐
|
☐
|
|
|
|
|
|
(C) Byron G. Wong
|
☐
|
☐
|
☐
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
To ratify the Kesselman Kesselman, a member firm of PricewaterhouseCoopers International Limited as independent auditors of the Company for 2019.
|
☐
|
☐
|
☐
|
|
|
|
|
3. |
To approve, in a non-binding, advisory vote, the compensation of our named executive officers
|
☐
|
☐
|
☐
|
|
|
|
|
Note:
Such other business as may properly come before the meeting or any adjustment or postponement thereof.
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
This proxy is solicited on behalf of the Board of Directors of the Company. This proxy, when properly executed, will be voted in accordance with the instructions given above. If no instructions are given, this proxy will be voted "FOR" the election of each Director nominee and “FOR” proposals 2 and 3.
|
||||
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.
|
☐
|
|
|
|
|
|
|
| Signature of Stockholder |
|
Date:
|
|
Signature of Stockholder |
|
Date: |
|
|
Note:
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|